NEW YORK (GenomeWeb News) – Ambry Genetics said Friday that it has purchased a Genome Analyzer from Illumina that it plans to use in conducting pharmacogenomics services for customers.
The Aliso Viejo, Calif.-based genetic testing firm said that it has already begun running research samples on the GA with its probe capture technology.
“To date we’ve run assays with hundreds of genes on the probe capture technology; with new bioinformatics software, SNP annotation and exon identification, we’ve been able to find many novel mutations,” Ambry CEO Charles Dunlop said in a statement.